The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Phase III Study Compared Neoadjuvant Therapy with Lapatinib or Trastuzumab for Early Breast Cancer

December 10, 2010 4:34 am | by AACR | News | Comments

SAN ANTONIO - Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer...


NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study

December 10, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

SANTA CLARA, Calif., Dec. 10, 2010 /- NewCardio, Inc., (OTC Bulletin Board: NWCI ) a cardiovascular diagnostic solutions developer, today presented the results from a blinded drug safety study conducted by the Cardiac Safety Research Consortium (CSRC) to evaluate the performance of...


Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension

December 10, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Dec. 10, 2010 /- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial...


HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock

December 10, 2010 4:32 am | by Bio-Medicine.Org | News | Comments

FRAMINGHAM, Mass. and SYDNEY, Dec. 10, 2010 /- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the pricing of a public offering of $125 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf...


A Magnetic Shortcut to Clinical Trials

December 9, 2010 8:34 pm | by Massachusetts Institute of Technology | News | Comments

Finding effective drug dosages using MRI could accelerate drug development.


Buprenorphine treatment produces improved outcome for babies born addicted

December 9, 2010 4:37 pm | by EurekAlert | News | Comments

(Vanderbilt University Medical Center) Babies born into the world addicted to drugs because of their mother's dependence on pain medication, or opioids, may be weaned off the substance more comfortably, with a shorter hospital stay and at a reduced cost, if the mother receives a...


Covidien Receives FDA 510(k) Clearance for the iDrive(TM) Powered Stapling System

December 9, 2010 4:35 pm | by Covidien | News | Comments

Company's first powered stapling system provides precision, control, access and visibility during open surgical procedures NORTH HAVEN, Conn., Dec 02, 2010 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in surgical...


Covidien Announces the Launch of Three New Platforms for its Puritan Bennett(TM) 840 Ventilators

December 9, 2010 4:34 pm | by Covidien | News | Comments

Puritan Bennett(TM) 840 Neonatal, Universal and Pediatric-Adult Ventilators Deliver Comprehensive Ventilation to a Broad Range of Patients BOULDER, Colo., Dec 09, 2010 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in...


Community Health offers to buy Tenet for $3B

December 9, 2010 1:46 pm | by The Associated Press | News | Comments

Community Health Systems Inc. is taking its $3 billion cash and stock offer for rival hospital operator Tenet Healthcare Corp. public, in a move to rally shareholder support for the deal.Tenet shares surged nearly 50 percent in aftermarket trading, rising $2.04 to $6.30.Community Health said...

Cigna buys back $300M of senior notes due in 2018

December 9, 2010 1:45 pm | by The Associated Press | News | Comments

CIGNA Corp. said Thursday that it will buy back $300 million worth of senior debt due in 2018.The health insurance company, based in Philadelphia, said that bondholders have until Dec. 15 to offer up their notes.The purchase price will be calculated by adding .45 percent to the yield of the...

New Surgeon General Report on Smoking and Disease Caps Successful Year of Federal Anti-Tobacco Action, AACR Says

December 9, 2010 1:32 pm | by AACR | News | Comments

WASHINGTON, D.C. - The American Association for Cancer Research commends the U.S. Office of the Surgeon General for its continued focus on tobacco, one of most pressing public health issues of our time. The Surgeon General today released a new report, How Tobacco Smoke Causes Disease,...


Cholera strain evolves new mechanism for causing disease

December 9, 2010 12:33 pm | by EurekAlert | News | Comments

(American Society for Microbiology) New clinical strains of cholera appear to have evolved a distinctly different mechanism to cause the same disease according to research published in the current issue of the online journal mBio.


Transformation at top of agenda for CPMRC's annual conference in Jan. 2011

December 9, 2010 12:33 pm | by EurekAlert | News | Comments

(Elsevier) The 19th International Conference (Jan. 19-22, 2011) of the CPM Resource Center, an Elsevier company and leader in assisting health care organizations improve practice at the point of care, will focus on transformational leadership and feature advice from many business...


Cancer prevention expert honored for innovative tobacco research

December 9, 2010 11:32 am | by EurekAlert | News | Comments

(University of Texas M. D. Anderson Cancer Center) Behavioral scientist and tobacco-cessation expert, Alexander V. Prokhorov, M.D., Ph.D., at the University of Texas MD Anderson Cancer Center is the recipient of the 2011 American Society of Preventive Oncology Joseph W. Cullen Memorial...


Former Aetna CEO James T. Lynn dies at 83

December 9, 2010 10:45 am | by The Associated Press | News | Comments

Managed care company Aetna Inc. said Thursday former Chairman and CEO James T. Lynn died this week in Maryland. He was 83.Lynn served as chairman and CEO for the Hartford, Conn., insurer from 1984 until he retired in 1992. He joined the company's board in 1978.Before joining Aetna, Lynn worked...


You may login with either your assigned username or your e-mail address.
The password field is case sensitive.